Change of Registered Office Address

31 March 2015

Midatech Pharma PLC

("Midatech")

Change of Registered Office Address

Midatech announces that it has changed its registered office address. The new registered office address for Midatech is:

65 Innovation Drive

Milton Park

Abingdon

Oxfordshire

OX14 4RQ

Enquiries:

Midatech Pharma plc

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

Consilium Strategic Communications

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

midatech@consilium-comms.com

About Midatech Pharma PLC

Midatech Pharma is a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs. The Group has a strong pipeline of product candidates in clinical and pre-clinical development with a clear focus on the key therapeutic areas of diabetes, cancer and neurological/ophthalmological diseases.

Central to Midatech's business are two platform technologies that may be used alone or potentially in combination and are designed to enable the targeted delivery ('right place') and controlled release ('right time') of existing drugs. Midatech's core platform is a pioneering drug conjugate delivery system based on gold-nanoparticles (GNPs) combined with existing drugs for targeted release at specific organs, cells or sites of disease. The Group's secondary platform (acquired through the acquisition of Q Chip) involves the consistent and precise encapsulation of active drug compounds within polymer microspheres that are designed to release the drug into the body in a highly controlled manner over a prolonged period of time.

The Group is collaborating with a number of universities, speciality and major pharmaceutical companies to develop its platform technologies into a broad number of products in order to achieve a range of potential revenue opportunities within priority therapeutic areas.

Midatech operates an in-house state-of-the-art nanoparticle manufacturing facility, based in Bilbao, Spain. The site has capacity for manufacturing sufficient materials for clinical trials and is fully licensed by the Spanish Medicines Agency for European compliance.

The Group is headquartered in Oxford, UK and employs 49 staff including 14 Oxford, UK, 17 in Cardiff, UK and 18 in Bilbao, Spain. Across the Group there are 32 qualified scientists.

Midatech Pharma is quoted on the AIM segment of the London Stock Exchange under the symbol MTPH.

For further company information see www.midatechpharma.com